Medicines Control Agency will take until Sept. 27 to consult on a proposal that would prohibit sale, supply, importation of unlicensed medicinal products containing kava, agency says July 18; consultation document will be available on 1MCA Web site this week. For products with marketing authorizations, Committee on Safety of Medicines will issue a final report after considering comments from kava marketers. UK supplement industry agreed in December to pull kava supplements from store shelves while MCA reviewed herbal's safety (2"The Tan Sheet" Dec. 24, 2001, p. 14)...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
The UK’s autumn budget failed to introduce any widespread changes for pharma, but scale-ups and innovators could benefit from changes to enterprise and investment schemes. Some industry voices warn of underinvestment in the MHRA and innovative medicines.
Decentralizing clinical research demands rethinking accountability and logistics to prevent gaps that could compromise safety and trial integrity.
The European Commission says it will soon publish an updated study on the impact of the Urban Waste Water Treatment Directive on the pharmaceutical and cosmetics industry and that it would support member states in avoiding “unintended consequences.”
While there is a general shift towards alignment and collaboration in health technology assessments in the EU under the new HTA Regulation, member states still have “their own recipe” when it comes to making reimbursement decisions.
The Medicare negotiated price is slightly higher than the Most Favored Nation price recently announced by the Trump Administration.
Aspen Neurosciences and BlueRock Therapeutics see hope for artificial intelligence to improve the quality of cell therapies to replace dopaminergic neurons in Parkinson's disease.
While Japan tries to balance its healthcare costs, the major US industry group is concerned reimbursement pricing practices in the country could influence US levels under Trump's MFN policy.
